Actively Recruiting
Study of B7-H3.CD28Z.CART Cell Therapy with Chemotherapy in Children and Young Adults with Recurrent or Progressive Brain Tumors Expressing B7-H3
Led by Robbie Majzner · Updated on 2026-09-03
70
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a cell therapy called B7-H3.CD28Z.CART in children and young adults with recurrent or progressive brain tumors. This trial targets tumors that have returned or worsened and focuses on tumors expressing the B7-H3 protein, which is found in many tumor cells. The study is a Phase 11b open-label trial conducted at a single institution, involving dose escalation and expansion stages to determine safe dosing and potential benefits. Participants receive a preparatory chemotherapy regimen of fludarabine and cyclophosphamide to prepare the body for the cell therapy. The treatment includes an intravenous infusion of the B7-H3 CAR T cells on Day 0, followed by up to eight intracerebroventricular ICV infusions every 28 days, depending on clinical response. The study uses a modified 33 dose escalation design in standard and high-risk groups to identify the maximum tolerated dose and recommended Phase 2 dose. Participants undergo baseline visits and apheresis to collect T cells before treatment. After infusions, follow-up visits occur every three months for two years, then annually for up to 13 more years to monitor long-term effects. Researchers assess manufacturing success, dose tolerance, treatment responses, adverse events, survival, and progression-free survival. The total participation can last up to 15 years, allowing thorough safety and efficacy monitoring.
CONDITIONS
Brief Title
B7-H3.CD28Z.CART in CNS Neoplasms
Research Team
S
Susan Chi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here